Eikon Therapeutics filed for a U.S. IPO, positioning the structural biology and drug‑discovery company as an early test of public appetite for biotech in 2026. The filing follows a period of renewed investor interest in platform companies that combine high‑throughput microscopy and computational discovery. Market watchers flagged Eikon’s filing as a potential bellwether for whether recent positive signals—like Aktis’s successful IPO—will translate into a broader reopening of the biotech public market.